newsfilter
← Latest News
GlobeNewswire·

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of